Humanized, Dual-Affinity Re-Targeting, Or (Dart), Molecule That Recognizes Both Cd123 And Cd3
Chronic Myeloid Leukemia
City of Hope Medical Centermonoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
78 Active assets in the Chronic Myeloid Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nilotinib Novartis Pharmaceuticals | Phase 4 | BBB |
Cyclophosphamide City of Hope Medical Center | Phase 3 | BBB |
Methotrexate M.D. Anderson Cancer Center | Phase 3 | BBB |
Romidepsin Center for International Blood and Marrow Transplant Research | Phase 2 | BBB |
Therapeutic Allogeneic Lymphocytes University of Chicago | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
Humanized, Dual-Affinity Re-Targeting, Or (Dart), Molecule That Recognizes Both Cd123 And Cd3 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →